Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Roche

Oncology drugs fuel growth

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Financial Report: Roche 4Q13

4Q Revenues: 11.9 billion CHF (+7%)

4Q Earnings: not reported

FY Revenues: 46.8 billion CHF (+3%)

FY Earnings: 11.4 billion CHF (+18%)

Comments: Pharma sales rose 3% to 36.3 billion CHF in 2013, hampered 4% by a strong Swiss franc. For the full year, Oncology products led the growth trend, with breast cancer drugs up 14% to 6.6 billion CHF (at CER). Avastin sales grew 13% to 6.3 billion CHF, while Rituxan revenues were up 6% to 7.0 billion CHF. Lucentis revenues were up 15% to 1.7 billion CHF. In 4Q13, Rituxan revenues were up 7%, Avastin was up 13%, Lucentis was up 22%, and Herceptin rose 7%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics